Cancers, Vol. 12, Pages 520: Intratumoral Heterogeneity and Longitudinal Changes in Gene Expression Predict Differential Drug Sensitivity in Newly Diagnosed and Recurrent Glioblastoma

Conclusions: Our results provide a transcriptional rationale for the lack of significant therapeutic benefit from temozolomide in patients with recurrent glioblastoma. Our findings imply that the spectrum of potentially effective drugs is likely to differ between newly diagnosed and recurrent glioblastomas and underscore the merits of glioblastoma stem cells as prognostic models for identifying alternative drugs and predicting drug response in recurrent glioblastoma. With the majority of recurrent glioblastomas being inoperable, glioblastoma stem cell models provide the means of compensating for the limited availability of recurrent glioblastoma specimens.

Source: Cancers - February 23, 2020 Category: Cancer & Oncology Authors: Ella L. Kim Maxim Sorokin Sven Rainer Kantelhardt Darius Kalasauskas Bettina Sprang Julian Fauss Florian Ringel Andrew Garazha Eugene Albert Nurshat Gaifullin Christian Hartmann Nicole Naumann Sven-Ern ö Bikar Alf Giese Anton Buzdin Tags: Article Source Type: research